Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724349 | SCV000230323 | pathogenic | not provided | 2014-11-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001389657 | SCV001591100 | pathogenic | Neuronal ceroid lipofuscinosis | 2023-11-09 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu358Alafs*4) in the CLN5 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 50 amino acid(s) of the CLN5 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with neuronal ceroid lipofuscinosis (PMID: 19309691, 20157158, 31105743). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 56526). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000049939 | SCV001977489 | pathogenic | Neuronal ceroid lipofuscinosis 5 | 2021-08-10 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000049939 | SCV004214397 | pathogenic | Neuronal ceroid lipofuscinosis 5 | 2023-01-28 | criteria provided, single submitter | clinical testing | |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049939 | SCV000082348 | probable-pathogenic | Neuronal ceroid lipofuscinosis 5 | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |